Mink Therapeutics Inc (INKT) USD0.00001
MiNK Therapeutics, Inc. is a biopharmaceutical company. The Company is specialized in discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). The Company offers platform, which is designed for reproducible manufacturing for off-the-shelf delivery. Its product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is in multiple Phase I clinical trials, which is used for the treatment of multiple myeloma.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.